Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform
Open Access
- 20 February 2019
- journal article
- research article
- Published by Elsevier BV in SLAS Discovery
- Vol. 24 (3), 346-361
- https://doi.org/10.1177/2472555218823171
Abstract
No abstract availableKeywords
Funding Information
- FP7 Health (603240)
This publication has 32 references indexed in Scilit:
- Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)The Lancet Neurology, 2013
- Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières Experience in the Democratic Republic of the CongoClinical Infectious Diseases, 2012
- The Relevance of Higher Plants in Lead Compound Discovery ProgramsJournal of Natural Products, 2011
- Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in miceMolecular Microbiology, 2010
- Development and validation of a cytochrome c-coupled assay for pteridine reductase 1 and dihydrofolate reductaseAnalytical Biochemistry, 2009
- Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trialThe Lancet, 2009
- Requirements for a lead compound to become a clinical candidateBMC Neuroscience, 2008
- Antileishmanial Constituents of the Panamanian Endophytic Fungus Edenia sp.Journal of Natural Products, 2008
- Secondary chemicals protect mould from fungivoryBiology Letters, 2007
- Antimalarial Activities of Peptide Antibiotics Isolated from FungiAntimicrobial Agents and Chemotherapy, 2001